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Heatmaputralization properties of HIV-1 in India to optimally design and test vaccines. For
this reason, a functional Env clone was obtained from each of ten newly acquired, heterosexually transmitted
HIV-1 infections in Pune, Maharashtra. These clones formed a phylogenetically distinct genetic lineage within
subtype C. As Env-pseudotyped viruses the clones were mostly resistant to IgG1b12, 2G12 and 2F5 but all
were sensitive to 4E10. When compared to a large multi-subtype panel of Env-pseudotyped viruses
(subtypes B, C and CRF02_AG) in neutralization assays with a multi-subtype panel of HIV-1-positive plasma
samples, the Indian Envs were remarkably complex. With the exception of the Indian Envs, results of a
hierarchical clustering analysis showed a strong subtype association with the patterns of neutralization
susceptibility. From these patterns we were able to identify 19 neutralization cluster-associated amino acid
signatures in gp120 and 14 signatures in the ectodomain and cytoplasmic tail of gp41. We conclude that
newly transmitted Indian Envs are antigenically complex in spite of close genetic similarity. Delineation of
neutralization-associated amino acid signatures provides a deeper understanding of the antigenic structure
of HIV-1 Env.
© 2008 Elsevier Inc. All rights reserved.Introduction
Genetic variability in the envelope glycoproteins of HIV-1 is one of
the most important obstacles to overcome in the development of an
effective vaccine. These glycoproteins form a trimolecular complex of
three surface gp120 molecules bound non-covalently to three
transmembrane gp41 molecules on the virus surface, where the
trimer spike mediates cell attachment and subsequent membrane
fusion events that allow the virus to enter cells (Wyatt and Sodroski,
1998). Neutralizing Abs block virus entry by binding and disabling the
trimeric Env spike (Crooks et al., 2005). A high rate of mutation,
combined with immune selection pressures and super-infections,er are those of the authors and
ters for Disease Control and
l rights reserved.have given rise to multiple genetic subtypes and circulating
recombinant forms (CRFs) of the virus that need to be targeted by a
globally effective vaccine. Genetic variability poses intricate problems
for neutralizing Abs by altering amino acid sequences in core epitopes
and by introducing structural changes in the gp120 molecule that
shield key epitopes from antibody recognition (Pantophlet and
Burton, 2006).
Over 90% of viral variants that drive the current global epidemic
encompass six genetic subtypes of groupM HIV-1: subtypes A, B, C, D,
CRF01_AE and CRF02_AG (Leitner et al., 2007; McCutchan, 2000).
Subtype C is the most prevalent subtype worldwide, accounting for
the majority of infections in sub-Saharan Africa, China (China is a B/C
recombinant that is mostly subtype C in Env) and India— the most
populous regions affected by HIV-1 (McCutchan, 2000; UNAIDS,
2006). Available sequences for the env, gag and nef genes, as well as
the limited full-length sequence data, suggest that subtype C strains
from India form amonophyletic lineage that segregates separately as a
subclade within the more diverse subtype C strains from Africa
506 S.S. Kulkarni et al. / Virology 385 (2009) 505–520(Agnihotri et al., 2004, 2006; Jere et al., 2004; Khan et al., 2007; Kurle
et al., 2004; Shankarappa et al., 2001). One potential consequence of
this limited env diversity in India could be a greater sharing of
neutralization determinants as recognized by serum from HIV-1-
infected individuals who reside in the same region (Lakhashe et al.,
2007). A similar observation was made in small groups of HIV-1
subtype C-infected individuals in South Africa (Bures et al., 2002;
Rademeyer et al., 2007), suggesting that neutralizing Ab-based
vaccine immunogens might have less epitope diversity to overcome
at a regional level.
There is an urgent need to understand how genetic diversity
impacts the neutralization properties of the virus, especially intra-
and inter-subtype differences within and between geographic
locations that could inﬂuence vaccine efﬁcacy. To facilitate these
efforts, recent reports have described separate panels of early,
sexually acquired reference strains for subtypes A (Blish et al., 2007),
B (Li et al., 2005) and C (Li et al., 2006b). Viruses from sexual
transmission are preferred because this is the major route of HIV-1
transmission world-wide (Galvin and Cohen, 2006; UNAIDS, 2006).
In addition, recently transmitted viruses (pre-seroconversion or
early seroconversion) might be the more relevant targets for
vaccines (Chohan et al., 2005; Derdeyn et al., 2004; Frost et al.,
2005; Keele et al., 2008; Zhang et al., 1993; Zhu et al., 1993). Finally,
it has been recommended that the reference strains be used as
molecularly cloned Env-pseudotyped viruses for greater stability,
reproducibility and quality control in neutralization assays (Mascola
et al., 2005). Here we describe the sequence, biologic phenotype and
neutralization properties of functional gp160 clones from sexually
acquired, newly transmitted HIV-1 subtype C infections in India and
we compare these clones to HIV-1 Envs from other parts of the
world.
Results
Demographics and biologic properties of the molecularly cloned gp160
genes
One functional gp160 clone was selected from each of ten HIV-1-
infected subjects either pre-seroconversion or during early serocon-
version (Table 1). PBMC for virus isolation were collected from March
1999 to November 2000 in the Pune district of Maharashtra state in
western India. Four viruses were isolated from females and six from
males. HIV-1 infections were reportedly acquired through hetero-
sexual contact in all cases. Viruses were isolated after a mean interval
of 18 days after p24 antigen conﬁrmation (range: 2–85 days). Mean
viral load was 1,422,309 HIV-1 RNA copies/ml (range: 3523–
6,633,880) and the mean CD4 count was 422 cells/ml (range: 296–
830). All molecularly cloned Env-pseudotyped primary viruses were
CCR5 tropic.Table 1
Functional HIV-1 gp160 clones from Pune, India
Env clonea Subtype CoR Gender Mo/Yr
isolated
HIV-00836-2.5 C R5 F 06/2000
HIV-16845-2.22 C R5 F 08/2000
HIV-16936-2.21 C R5 M 11/2000
HIV-25711-2.4 C R5 M 03/1999
HIV-25925-2.22 C R5 M 09/1999
HIV-0013095-2.11 C R5 F 04/2000
HIV-001428-2.42 C R5 F 08/2000
HIV-16055-2.3 C R5 M 03/1999
HIV-26191-2.48 C R5 M 05/2000
HIV-25710-2.43 C R5 M 03/1999
a All viruses were transmitted through heterosexual contact. Molecular clones were obta
b ND, not done.Genetic analysis of the Indian Envs
Phylogenetic analysis of full-length gp160 nucleotide sequences
showed that the 10 functional Env clones from India formed a
relatively conserved cluster within the more diverse subtype C (Fig. 1).
All clones contained an uninterrupted env open reading frame and
showed 100% conservation of cysteine residues that form the V1, V2,
V3, and V4 loops of gp120 (Fig. 2). Two additional cysteine residues
were present in the V1 loop of one clone (HIV-16845–2.22). Several
clones also exhibited variable placement of cysteine residues in the
gp41 cytoplasmic tail. Considerable amino acid sequence variability
was present in V1, V2, V4 and V5. Amino acid sequence variability in
V3 was relatively low, whereas a region of approximately 34 amino
acids immediately downstream of V3 that contains an amphipathic
a2-helix was remarkably variable, as is typical of subtype C viruses
(Gaschen et al., 2002; Gnanakaran et al., 2007; Li et al., 2006b).
Another typical observation was the considerable size variation in
V1, V2, V4 and V5 and little or no size variation in V3 (Fig. 2,
Supplementary Table 1). The total number of potential N-linked
glycans (PNLG) on gp160 ranged from 23–31 (mean=28.4), with a
mean of 24 sites in gp120 (range 19–27) and 4 sites in the second
heptad repeat (HR2) in gp41 (range 4–5). Eleven PNLG sites on gp120
and two on the gp41 ectodomain were highly conserved (Fig. 2).
Heaviest clustering of PNLG on gp120 was seen in V1, V2 and V4. Most
clones contained a single PNLG in V5.
Neutralization phenotype of the Indian Envs as assessed with common
reagents
All 10 Indian Env clones were characterized as Env-pseudotyped
viruses in neutralization assays with sCD4, four mAbs (IgG1b12, 2G12,
2F5, 4E10), TriMab, HIVIG and subtype B, C and D plasma pools.
Cognate targets for themAbs consist of a complex epitope overlapping
the CD4 binding site of gp120 in the case of IgG1b12 (Pantophlet et al.,
2003; Saphire et al., 2001), a glycan-speciﬁc epitope on gp120 in the
case of 2G12 (Calarese et al., 2003; Sanders et al., 2002; Saphire et al.,
2001), and two adjacent epitopes in the membrane proximal external
region (MPER) of gp41 in the case of 2F5 and 4E10 (Barbato et al.,
2003; Brunel et al., 2006; Hagen-Braun et al., 2006; Zwick et al., 2001).
The broadly cross-reactive neutralizing activity of these mAbs (Binley
et al., 2004) has attracted considerable interest for vaccine design.
A majority of the Indian Envs were sensitive to sCD4 at concentra-
tions ranging from 1.0 to 29. 0 μg/ml; only one clone (HIV-00836-2.5)
was resistant to sCD4 at the highest dose tested (50 μg/ml) (Table 2). As
with most subtype C Envs, all Indian Envs were resistant to 2G12 and
this resistance was associated with the absence of a PNLG at position
295 (HXB2 numbering; position 282 as numbered in Fig. 2) at the
N-terminal base of the V3-loop (Binley et al., 2004; Gray et al., 2006, Li








85 31,104 NDb EF117265
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2 534,557 830 EF117268
9 5,346,070 338 EF117274
19 3523 350 EF117271
ined from PBMC co-cultured virus isolates.
Fig. 1.Maximum likelihood tree indicating the phylogenetic relationships of the gp160 sequences used in the reference panel of sequences used to study neutralization phenotype.
The newly characterized Indian gp160 genes are clustered together within the more diverse group of subtype C Envs from Africa, represented here by twelve gp160 genes that are
recommended as standard reference reagents from South Africa and Zambia. The African sequences did not cluster by country, but there was a distinctive South African sub-cluster.
The CRF 02_AG sequences 271 and T33 are highly related. Values at nodes indicate the percentage of bootstraps in which the cluster to the right was found; only values of 78% or
greater are shown. The M group ancestor from the Los Alamos database was used as an outgroup.
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viruses from other parts of the world tend to be sensitive to this mAb
(Binley et al., 2004; Gray et al., 2006; Li et al., 2006b). These latter two
clones were among the least sensitive to sCD4 (ID50 of 29.0 and 17.
1 μg/ml), suggesting that the IgG1b12 epitope, when it is present, can
be targeted even when the CD4 binding site is partially masked.
RegardingMPER-speciﬁc mAbs, all 10 Indian Envs were sensitive to
4E10 whereas only one Env was sensitive to 2F5 (Table 2). The single
2F5-sensitive Env (clone 25711.2-4) was the only Env that contained a
DKW motif known to be a minimum requirement for 2F5 recognition(Binley et al., 2004; Li et al., 2005; Zwick et al., 2005). Many other
subtype C viruses lack this motif in gp41 and are reported to be 2F5
resistant (Binley et al., 2004; Gray et al., 2006; Li et al., 2006b). The
ability of 4E10 to neutralize all 10 clones is consistent with the
presence of a WFXI motif that is known to be important for 4E10
recognition (Binley et al., 2004; Li et al., 2005; Zwick et al., 2005). We
note that two clones (HIV-25710-2.43 and HIV-25711-2.4) contained a
PNLG in the 4E10 epitope that might be expected to shield against Ab
binding but this site does not appear to be glycosylated (Lee et al.,
1992).
Fig. 2. Alignment of deduced amino acid sequences for subtype C HIV-1 gp160 genes from India. Nucleotide sequences were translated, aligned, and compared with a consensus
sequence generated by MASE. Numbering of amino acid residues begins with the ﬁrst residue of gp120 and does not include the signal peptide. Dashes denote sequence identity,
while dots represent gaps introduced to optimize alignments. Small letters in the consensus sequence indicate sites at which fewer than 50% of the viruses share the same amino acid
residue. Triangles above the consensus sequence denote cysteine residues (solid triangles indicated sequence identity, while open triangles indicate sequence variation). V1, V2, V3,
V4, and V5 regions designate hypervariable HIV-1 gp120 domains. The signal peptide and Env precursor cleavage sites are indicated; “msd” denotes the membrane-spanning domain
in gp41; asterisks mark in-frame stop codons. Open circles highlight altered cysteine residues. Potential N-linked glycosylation sites (NXYX motif, where X is any amino acid other
than proline and Y is either serine or threonine) are bolded and underlined. Potential N-linked glycosylation sites that are conserved in at least 9 of the 10 clones are shaded.
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Fig. 2 (continued).
509S.S. Kulkarni et al. / Virology 385 (2009) 505–520Given the general resistance to 2G12, 2F5 and IgG1b12, it was not
unexpected that only one Indian Env was neutralized by TriMab
(mixture of IgG1b12, 2G12, and 2F5). This Env (HIV-26191-2.48) was
resistant to both 2G12 and 2F5 and was one of only two Indian Envsneutralized by IgG1b12. The inability of TriMab to neutralize the other
IgG1b12-sensitive Indian Env is explained by the sub-threshold
concentration of IgG1b12 in TriMab. Overall, TriMab does not appear
to be suitable positive control reagent for neutralization assays with
Table 2
Neutralization phenotype of pseudotyped viruses containing molecularly cloned Env genes from India
Virus ID50 in TZM-bl cells (plasma dilution)a ID50 in TZM-bl cells (μg/ml)a
Subtype B Pool Subtype C Pool Subtype D Pool HIVIG sCD4 IgG1b12 2G12 2F5 4E10 TriMab
HIV-00836-2.5 22 137 112 1223 N50 N50 N50 N50 1.8 N25
HIV-16845-2.22 b20 24 28 1018 1.0 N50 N50 N50 0.1 N25
HIV-16936-2.21 48 317 72 1001 4.4 N50 N50 N50 1.8 N25
HIV-25711-2.4 31 232 40 1513 29.0 25.9 N50 36.2 4.2 N25
HIV-25925-2.22 30 111 38 1448 12.9 N50 N50 N50 1.5 N25
HIV-0013095-2.11 60 157 56 327 1.1 N50 N50 N50 0.1 N25
HIV-001428-2.42 71 190 41 783 5.2 N50 N50 N50 10.1 N25
HIV-16055-2.3 b20 b20 24 1948 11.4 N50 N50 N50 1.7 N25
HIV-26191-2.48 b20 202 42 1986 17.1 4.9 N50 N50 3.1 14.1
HIV-25710-2.43 43 364 65 339 2.6 N50 N50 N50 0.2 N25
GMTb 27 119 47 991
a Values are the dilution (plasma samples) or concentration (HIVIG, CD4, IgG1b12, 2G12, 2F5, 4E10, TriMab) at which RLU were reduced 50% compared to virus control wells.
TriMab is an equal concentration mixture of IgG1b12, 2G12 and 2F5.
b GMT, geometric mean titer.
Fig. 3. Neutralization-sensitivity of the Indian Envs as determined with plasma samples
from chronically infected subjects in India and South Africa. Bar heights represent the
geometric mean titer (GMT) of neutralizing Abs against the indicated Env-pseudotyped
viruses. Black bars, plasma samples from 18 subjects in India. Gray bars, plasma samples
from 6 subjects in South Africa. Paired sets were compared by two-tailedMannWhitney
tests. Differences that were signiﬁcant (pb0.05) are designated with an asterisk.
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Envs (Table 2), appears to be more suitable because of its broad
reactivity against subtype C and other subtypes of HIV-1.
Among the three different HIV-1-positive plasma pools, the
Indian Envs were most sensitive to the subtype C pool, followed by
the subtype D and B pools, respectively (Table 2). Differences were
signiﬁcant (two-tailed Mann Whitney tests with a 95% conﬁdence
interval) for the C pool compared to the B pool (p=0.001) and D
pool (p=0.004) but not between the B and D pools (p=0.105).
Similar results were obtained when these same plasma pools were
assayed previously against a panel of subtype C Env clones from
South Africa and Zambia (Li et al., 2006b). In general, subtype C
viruses appeared to be more sensitive to neutralization by subtype C
plasmas than to subtype B and C plasmas from chronically infected
individuals.
We also compared the potency of HIVIG against the Indian Envs
and against a standard panel of 12 reference Envs each for subtypes B
and C. The Indian Envs were less sensitive to HIVIG (GMT=991 μg/ml,
Table 2) than subtype B and C reference Envs (GMT subtype B
panel=375 μg/ml, p=0.0009; GMT subtype C panel=407 μg/ml,
p=0.0016). No signiﬁcant difference was seen between the subtype
B and C reference Envs (p=0.6668).
Classiﬁcation of the Indian Envs as tier 2 viruses
A small fraction of HIV-1 variants are highly sensitive to
neutralization and are classiﬁed as tier 1 viruses whereas most
primary isolates are substantially less sensitive to neutralization
(classiﬁed as tier 2) and are considered more important to target with
vaccines (Mascola et al., 2005). In general, the difference in
neutralization sensitivity between tier 1 and tier 2 viruses has been
attributed to epitope exposure in the V3 loop and co-receptor binding
domain of gp120 (Bou-Habib et al., 1994; Li et al., 2006b; Vancott et al.,
1995; Xiang et al., 2002a, 2002b, 2003). Plasma samples from
presumed clade C HIV-1-infected individuals in India (n=18) and
South Africa (n=6) were used to characterize the general neutraliza-
tion phenotype of the Indian Env clones. As shown in Fig. 3, all 10
Indian Env clones were substantially less sensitive to neutralization
than the prototypic tier 1 viruses, MN and SF162.LS. In this regard, the
Indian Env clones exhibited a typical tier 2 phenotype.
The data in Fig. 3 were analyzed further to determine whether any
Indian Env clones were preferentially neutralized by HIV-1-positive
plasmas from either India or South Africa. Eight Env-pseudotyped
viruses were neutralized equally by both sets of plasmas. Of the
remaining three pseudoviruses, Env clone 16055-2.3 was signiﬁcantly
more sensitive to neutralization by the Indian plasma samples,
whereas Env clones 26191-2.48 and 25711-2.4 were signiﬁcantly
more sensitive to neutralization by plasmas from South Africa.Interestingly, these latter two Envs were the only Indian Envs that
were sensitive to IgG1b12 (Table 2).
Relationships by hierarchical clustering
Because of the close genetic similarity among the Indian Envs, it
was possible that they comprise a discrete antigenic group as
compared to subtype A, B, C and CRF02_AG Envs from other parts of
the world. To explore this possibility, agglomerative hierarchical
clustering of neutralization data with HIV-1-positive plasma samples
was used to determine whether subtype-speciﬁc neutralization
serotypes could be revealed. This strategy clusters Envs by their
susceptibility to a panel of antibodies or plasmas, while simulta-
neously clustering Abs and plasmas by their ability to neutralize a
panel of Envs. The robustness of the clusters was assessed through
bootstrap re-sampling of the data. We ﬁrst analyzed neutralization
data generated with the 6 individual subtype C plasma samples from
South Africa and the subtype B C, and D plasma pools as assayed
against a multi-subtype panel of 57 Env-pseudotyped viruses
(subtypes B, C and CRF02_AG), including viruses pseudotyped with
the 10 Indian Envs. Heatmap 1 (Fig. 4) shows that two main
neutralization clusters were identiﬁed, in which the upper cluster
Fig. 4. Heatmap 1. Hierarchical clustering analysis of neutralization results generated with HIV-1-positive plasma samples from South Africa and subtype B, C and D plasma pools.
Plasma samples from 6 HIV-1 subtype C-infected blood bank donors in Johannesburg, South Africa, and plasma pools from individuals infected with either HIV-1 subtype B, C or D,
were assayed against a multi-subtype panel of 57 Env-pseudotyped viruses, including viruses pseudotyped with each of the 10 Indian Env clones. The dendogram for pseudovirus
clustering is displayed on the left of the Heatmap, while the dendogram for the plasma clustering is displayed on the top. Env clones and plasma names are displayed at the tips of the
respective dendograms. The magnitude of neutralization (log IC50 values) are denoted by color, and the numbers that correspond to the colors in the key are the natural log of the IC50
value. A “Brewer” color palette (www.ColorBrewer.org) was used tomap neutralization values to colors: lower values are represented by less saturated light colors (e.g. light yellows),
while higher values of neutralization are represented bymore saturated dark colors (e.g. dark reds). Bootstrap values (the percentage of time a cluster was found among 1000 random
with replacement resamplings of the data) of themajor Env clusters are shownproximal to branch points; only high bootstrap values associated with the major groupings are shown.
Some of the pairs and triplets also had high boostrap values. The upper (U) cluster referred to in the text is marked; it is more neutralization-sensitive and dominated by African
subtype C sequences. The lower (L) clusters is less sensitive to neutralization and can be broken down into L1, dominated by the CRF02 AG envelopes, and L2, dominated by subtype B
Envs. The subtype C Envs from India were distributed throughout the Heatmap and are labeled on the right in green text.
511S.S. Kulkarni et al. / Virology 385 (2009) 505–520(U) was generally more neutralization-sensitive than the lower cluster
(L); both had 99% bootstrap support. As seen previously with mAbs
(Binley et al., 2004), there was evidence for subtype-related serotypes
in somuch as the subtype C Envs from South Africa and Zambiamostly
fell in the upper cluster whereas the subtype B reference Envs and the
CRF02_AG Envs mostly fell in the lower cluster. Bootstrap analysis of
the clusters show that further subdivisions of the two main clusters
may be made with good bootstrap support. Thus, distinct and
relatively homogenous subclusters were formed by a substantial
portion of the subtype B (L2) reference Envs and the CRF02_AG Envs(L1), with CRF02_AG being the most refractive overall to neutraliza-
tion. Surprisingly, the Env clones from India were scattered through-
out the Heatmap, and interspersed among some of the least sensitive
CRF02 and subtype B viruses.
That genetically similar Env clones from India would be dispersed
in a neutralization heatmap in which Envs that exhibit greater genetic
diversity showed some evidence for clustering was unexpected. It also
raised the question of whether the Indian Envs would exhibit
clustering when assayed with geographically matched HIV-1-positive
plasma samples. To address these questions, heatmap 2 (Fig. 5) shows
Fig. 5. Heatmap 2. Hierarchical clustering analysis of neutralization results generated with Indian HIV-1-positive plasma samples. Plasma samples from 18 chronic HIV-1 infected
individuals in Pune, India were assayed against a multi-subtype panel of Env-pseudotyped viruses, including viruses pseudotyped with each of the 10 Indian Env clones. Description
of the Heatmap is as described in the legend to Fig. 4. Indian Envs are shown in green. The highly neutralization-sensitive tier 1 Envs (SF162.LS and MN) cluster at the bottom of the
Heatmap.
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chronically infected individuals in Pune, India as assayed against
pseudoviruses containing subtypes A, B, and C Envs, including viruses
pseudotyped with the 10 subtype C Envs from India. Because of the
limited amount of plasma that was available, fewer Env-pseudotyped
viruses were assayed here than in heatmap 1, and the most resistant
viruses from subtype B and CRF02 were not tested, as these latter
viruses strongly contributed to the clustering pattern in the ﬁrst
heatmap. The second heatmap illustrates more of a continuum of
moderately susceptible viruses, with the exception of the two
laboratory-adapted strains at the bottom of the ﬁgure. Evidence for
subtype-related neutralization serotypes (neutralization clusters
predominantly containing Envs of one subtype) was not apparent
using this panel of plasma samples and Envs (disregarding the two
readily neutralized tier 1 viruses, MN and SF162.LS). Although the
lower clusters contained 10 of 12 members belonging to subtype C,
the remaining 10 subtype C Envs were scattered throughout the
dendogram. In particular, the 10 newly transmitted subtype C Envsfrom India displayed no obvious clustering and were dispersed
throughout the dendogram, as they were in Heatmap 1 (Fig. 4),
despite using geographically matched plasmas. In addition, the
subtype C plasma pool in Fig. 4 was from subjects in South Africa,
and it neutralized most Envs, with two geographic/subtype based
exceptions: Envs from CRF02 collected in West Africa (L1), which
tended to react very poorly with all of the plasmas tested, and a
handful of subtype C Envs from India (HIV-29525, -00836, -16055,
-16825). Interestingly, these same four Indian Envs were often quite
susceptible to individual plasma from India (Fig. 5). We conclude that
the Indian Env clones are antigenically diverse in spite of close genetic
similarity, suggesting that for these viruses relatively few amino acids
have a large effect on neutralization.
Amino acid signature pattern associations with neutralization clusters
The multiple neutralization clusters seen in Heatmap 1 (Fig. 4) led
to a search for amino acid signature patterns that associate with these
513S.S. Kulkarni et al. / Virology 385 (2009) 505–520clusters. Sequences of the Env clones in the main neutralization
clusters of Heatmap 1 were analyzed using the techniques ﬁrst
developed by (Bhattacharya et al. 2007) in the context of associating
genetic mutations with HLA; these methods factor in phylogenetics
when statistically assessing amino acid substitutions that correlate
with an attribute of the virus. We used these techniques to search for
associations between genetic mutations and neutralization clusters in
away that controls for the phylogenetic history and related lineages of
the sequences. Results for 47 associations with qb0.2 between a given
amino acid position and neutralization phenotype revealed 19
signature sites in gp120 and 14 signature sites in gp41 (Fig. 6). More
detailed information on these amino acid signatures, including their
position (HXB2 positional numbering), the particular amino acids, the
neutralization cluster with which they are associated, p-value, q-
value, and odds ratio of the association are shown in Supplemental
Materials (Supplementary Table 2).
Signature amino acid positions in gp120, as given in Fig. 6 and
Supplementary Table 2, were mapped to spatial locations on the
gp120 molecule to illuminate potential biologic signiﬁcance. Fig. 7
(top left) displays these signature sites on a gp120 core structure
corresponding to the X-ray crystal structure of CD4 bound to YU2
gp120 with modeled loops (Kwong et al., 2000). Four signature sites
occurred in the N-terminal region of gp120 that could not be displayed
because no structure is available in this region. Among the sites thatFig. 6. Signature amino acid positions associated with neutralization clusters. Shown are all si
the Los Alamos database. Above each signature is its numerical position (HXB2 numbering). C
light orange; U3, red; L, light blue; L1, medium blue; L2, dark blue. Upper case letters are use
denote that the amino acid tends to be mutated away in the group. If a subcluster and cluster
statistics and show only the most signiﬁcant one. The complete list of sites and statistical dcould be displayed, several are of potential interest. For example, L1
cluster-associated signatures at positions 121 in β2 and 165 in the V2
loop occur in the region of gp120 that undergoes substantial
conformational motions upon binding to CD4 (Kwong et al., 2002;
Xiang et al., 2002a, 2002b). Additionally, as illustrated by the contact
region for mAb 17b (Fig. 7, bottom left), signatures at positions 121 (L1
cluster) and 208 (U cluster) are potentially (or proximal to residues)
involved in CCR5 co-receptor binding (Reeves et al., 2004; Rizzuto and
Sodroski, 2000; Rizzuto et al., 1998). A signature at position 281,
associated with the neutralization-sensitive U cluster, is in a contact
region for both sCD4 and b12 (Fig. 7, bottom right) (Zhou et al., 2007).
A signature associated with the neutralization-sensitive U cluster
(position 336) occurred at the N-terminus of the amphipathic α2-
helix (Gnanakaran et al., 2007) immediately downstream from the V3-
loop (Fig. 7, top left).
Signatures involving PNLG sequons occurred at positions 295 (the
signature site is the T at position 297, immediately adjacent to the N-
terminus of the V3-loop), position 392 (the site is the T at position 394
in the V4 loop) and at the N at position 448. As shown in Fig. 7 (top
left), all three PNLG appear on one face of the molecule, the so called
‘silent face’ of gp120 (Wyatt et al., 1998). Preservation of PNLG at
position 392 was associated with the neutralization-resistance L
cluster. Loss of PNLG at positions 295 and 448 was associated with the
neutralization-sensitive U cluster. Although mAb 2G12 is presumedgnature positions having qb0.20 as alignedwith M group ancestor gp160 sequence from
olors indicate the group of the association in Heatmap 1: U, yellow; U1, dark orange; U2,
d denote that an amino acid is associated with the group. Lower case letters are used to
were both associated with the same amino acid pattern, we assumed they were related
etails can be found in Supplemental Materials (Table S1).
Fig. 7. Neutralization cluster-associated amino acid signatures mapped on gp120 and gp41. Color coding is the same as is in Fig. 6. Top left: Signature positions mapped on a CD4-
bound gp120 core structure with modeled loops; the three PNLG signature positions are shown separately for clarity. Top right: Signature positions shown on a cartoon model of
gp41. Bottom left: Signature positions 281 and 121 in relationship to the receptor and 17B binding domains on gp120 crystal structure (53). Bottom right: Signature position 281 in
relationship to the b12 binding domain on gp120 crystal structure [REF 107]. In the bottom ﬁgures, CD4 and antibody contact regions in gp120 aremarked in light green andmagneta,
respectively. Contacts are deﬁned based on crystal structures with a deﬁnition of heavy atom distance less than 7Å.
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sites just mentioned are part of the 2G12 epitope (Sanders et al., 2002;
Scanlan et al., 2002), suggesting that glycans originating in these three
positions can be in close spatial contact. The consistent pattern of loss
of PNLG being associated with greater sensitivity in neutralization
clusters suggests that although a large fraction of accessible surface of
gp120 is covered by carbohydrates, neutralization susceptibility can
be modulated with loss/gain of glycans in a relatively small region
within the silent face.
Because of a lack of three-dimensional structural data, signature
amino acid positions in gp41, as given in Fig. 6 and Supplementary
Table 2, were plotted in a cartoon diagram (Fig. 7, top right). There
were ﬁve signature sites in the ectodomain and nine signature sites in
the cytoplasmic tail of gp41. As might be expected, no signature sites
occurred in the transmembrane domain. One signature in the
ectodomain occurred in the fusion peptide (position 518) (Freed and
Martin, 1995; Kowalski et al., 1987) and another occurred in the 2F5
epitope (position 667) (Zwick et al., 2005). A third signature in the
ectodomain (position 620) occurred between the two heptad repeat
regions and has been implicated to modulate virus entry (Jacobs et al.,
2005). Of the nine signature sites in the gp41 cytoplasmic tail, four
were in the N-terminal region and were associated with neutraliza-
tion resistant clusters (L clusters), whereas the other ﬁve were in the
C-terminus and were associated with neutralization sensitive clusters
(U clusters). Both regions play important roles in virus infectivity and
in the incorporation of Env during virus assembly (Dubay et al., 1992;
Freed and Martin, 1996; Yu et al., 1993).
The number of PNLG sites at positions 295, 392, 448 (HXB2
numbering), when considered in combination, was signiﬁcantly lower
(Wilcoxon p=0.005) in the more neutralization-sensitive U cluster
compared to the more resistant L cluster, in accord with expectations
that resistance can be conferred by increasing the extent of
glycosylation. In addition, there was a signiﬁcant difference in thetotal number of PNLG sites on gp120 between the U and L
neutralization clusters, with the more sensitive U cluster having
fewer PNLG sites (p=0.004) and generally smaller gp120 lengths
overall (p=0.0003) (Fig. 8). These two overall measures were mostly
related to speciﬁc reductions in the number of PNLG in V4, and
reductions in V1 and V4 loop lengths, the latter being signiﬁcantly
reduced in size in the more neutralization sensitive U cluster (Fig. 8,
Supplementary Table 2). The p-values presented are uncorrected, and
we did 10 tests; thus all survive a Bonferroni correction except for
differences in the number of PNLG sites in V4, which is just a trend by
this criteria.
Given the clear subtype associations seen in Heatmap 1, if loop
length and the number of PNLG are subtype-associated, some other
aspect of genetic subtype-associated sequence diversity could be the
origin of the observed neutralization susceptibility, and the loop length
and number of PNLG may simply be confounding variables. In this
regard, we corrected for the phylogeny and non-independence of
points in twoways. First, we used a generalized linearmodelwherewe
included the gp120 and V loop lengths, number of glycosylation sites,
and genetic subtype of the virus in the model (Hastie and Pregibon,
1992). Subtype C, excluding those from Pune, and the lengths of gp120,
V1, V2, V4, and V5were each found to contribute signiﬁcantly, with the
signiﬁcant parameters being non-Indian subtype C (p=0.0005), the V2
loop length (p=0.0009) and the lengths of gp120, V2, V3 and V5 (each
with pb0.003). If the subtype C Envs from India were included in the
total subtype C Envs, because of their variation in the neutralization
susceptibility proﬁles, the C subtype became much less predictive
(p=0.02). None of the tallies of the number of PNLG contributed
signiﬁcantly to the model, presumably because they correlate with
loop length, and lengths were more predictive.
As a second test, we used Felsenstein's method of phylogenetic
contrasts (http://liv.bmc.uu.se/cgi-bin/emboss/help/fcontrast) to
explore the impact of phylogenetic relationships on the PNLG and
Fig. 8. Length of gp120 and its variable regions in association with neutralization phenotype clusters U and L. The top p-value given is based on a direct comparison that does not
correct for the phylogeny, and uses a non-parametric rank sum test to compare distributions of sequence lengths in the more neutralization-sensitive U cluster (grey bars) and the
more neutralization-resistant L cluster (open bars). V3 is not shown because it does not often vary in length. The lower p-value in each panel is calculated using a GLM, a statistic that
indicated that the loop length associations were highly predictive of the neutralization susceptibility proﬁle and cluster, independent of the subtype.
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that this method looks for associations between continuous variables,
we could not use the U and L classiﬁcations as we did for the other
tests. Instead we used the overall geometric mean of the neutraliza-
tion scores for each Env. Using this strategy we found that only V5
length had an association with the geometric mean of the neutraliza-
tion scores, and this was marginal with p=0.006.
Discussion
This is the ﬁrst description of the neutralization properties of
newly transmitted subtype C HIV-1 Envs from sexually acquired
infections in India. Pune in Maharashtra state, where these viruses
originated, is one of the main epicenters of HIV-1 infections in India.
Moreover, the epidemic here as in other parts of India is drivenmostly
by heterosexual transmission (National AIDS Control Organization,
2005). Current molecular surveillance data indicate a predominance
of subtype C HIV-1 across India (Maitra et al., 1999; UNAIDS, 2006)
with a minor proportion of infections caused by subtypes A and B
(Baskar et al., 1994; Jameel et al., 1995; Tsuchie et al., 1995) and
intersubtype recombinants (Lakhashe et al., in press; Lole et al., 1999;
Tripathy et al., 2005). In fact, all 10 Indian Envs studied here were pure
subtype C. An important distinguishing feature of these Indian Envs
was their close genetic similarity to one another compared to subtype
C Envs from other parts of the world. Similar phylogenetic clustering
of HIV-1 env genes has been observed in multiple Indian states
(Agnihotri et al., 2004, 2006; Khan et al., 2007; Shankarappa et al.,
2001), leading to the suggestion that much of the Indian epidemic
arose from the introduction of a single HIV-1 strain into the country
out of the epidemic in Southern Africa (Gaschen et al., 2002;
Shankarappa et al., 2001). Our limited sequence data do not disagree
with this conclusion, at least for the period of time prior to when our
viruses were isolated (1999–2000). A recent report on viruses
collected from 1995 to 2004 suggested that Env diversity within
Indian subtype C has increased in recent years (Khan et al., 2007).
The Indian Envs described here resembled subtype C Envs from
other parts of the world in their general resistance to 2G12 and 2F5
and their general sensitivity to 4E10. They were different from other
subtype C viruses by their infrequent neutralization by IgG1b12. Thus,
epitopes for several of the most broadly neutralizing mAbs (e.g.,
IgG1b12, 2G12, 2F5) appear to be under-represented on Indian
subtype C HIV-1 variants. The Env clones described here might be
useful in delineating alternate epitopes for broadly neutralizing Abs
on subtype C viruses.
Because these are the ﬁrst functional molecular Env clones to be
described from India, the genetic and neutralization properties of the
Envs were characterized in greater detail, especially in comparison toother functional Env clones. In particular, our inclusion of a large
number of viruses of different genetic subtypes permitted an
examination of intra- and inter-subtype relationships. One of the
more interesting and unexpected observations was that, in spite of
close genetic similarity, the neutralization determinants on the Indian
Envs appeared to be particularly complex. Evidence for this came from
an agglomerative hierarchical clustering analysis of neutralization
data generated with individual HIV-1-positive plasmas and a multi-
subtype panel of HIV-1-positive plasma pools. In the analysis of two
separate datasets, the Indian Envs were less likely to cluster as a result
of similar neutralization susceptibility patterns than were subtype A,
B, C and CRF02_AG viruses from other parts of theworld. This was true
even when the data being analyzed were generated with HIV-1-
positive plasma samples from the same region where the Indian Envs
originated as conditions that should be favorable for a clustering effect
within the Indian Envs. The multiple cases of viruses that did cluster
showed evidence of subtype-related serotypes, suggesting that a
similar analysis of substantially larger datasets of this kind could yield
a classiﬁcation system to group HIV-1 variants according to neutra-
lization serotype. Our preliminary data suggests that if such grouping
is possible, neutralization serotypes and genetic subtypes will
partially overlap. Results of a similar analyses of neutralization data
generated with HIV-1-positive serum samples and multiple subtypes
of HIV-1 primary isolates also suggested that some neutralization
determinants are subtype-speciﬁc whereas others are partially shared
(Brown et al., in press; Rademeyer et al., 2007). The degree of sharing
could impact the ability of a vaccine to elicit broadly neutralizing Abs,
at least between subtypes A, B and C. Evidently, the extent of cross
neutralizationwill depend on Ab speciﬁcity in as much as some of the
neutralizing mAbs mentioned above are relatively subtype-speciﬁc.
The discrete neutralization clusters seen in one of our Heatmaps
(Heatmap 1, Fig. 4) prompted a search for cluster-associated genetic
properties that might explain the general differences in overall
neutralization-sensitivity. Our observations lend support to previous
ﬁndings (Bou-Habib et al., 1994; Chohan et al., 2005; Derdeyn et al.,
2004; Gray et al., 2007; Li et al., 2006a; Moore and Sodroski, 1996;
Reeves et al., 2004; Reitter et al., 1998; Sagar et al., 2006; Wei et al.,
2003; Wyatt et al., 1995) showing that greater neutralization-
sensitivity among tier 2 primary HIV-1 isolates is associated with
smaller gp120s that contain shorter variable loops and fewer PNLG. In
addition, our ﬁndings suggest that greater neutralization-sensitivity is
more common for subtype C viruses from Africa compared to subtype
B and CRF02_AG viruses, at least as deﬁned with the HIV-1-positive
plasma samples tested here. A similar observation was made recently
in both the PBMC and TZM-bl assays (Brown et al., in press).
Collectively, these observations are consistent with masking mechan-
isms playing an important role in shaping the general neutralization
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available, an ability to predict these masking mechanisms by genetic
analysis could facilitate vaccine development.
A separate analysis identify 19 neutralization cluster-associated
amino acid signatures on gp120 and 14 additional signatures that
spanned the ectodomain and cytoplasmic tail of gp41. Interestingly,
two of the signatures in gp120, one effecting a PNLG in the α2-helix
(position 336) and another in the central portion of V4 (position 393),
were previously identiﬁed as signatures of escape from autologous
neutralization in subtype C HIV-1-infected individuals (Rong et al.,
2007). Another signature (position 281) is located in the gp120
binding site for both sCD4 and mAb b12 (Zhou et al., 2007) that has
been shown also to be a major target for broadly neutralizing
antibodies in serum from a small subset of HIV-1-infected individuals
(Li et al., 2007). Also, a signature at position 121 resides in the bridging
sheet that contributes to the coreceptor binding domain of gp120
(Reeves et al., 2004; Rizzuto and Sodroski, 2000; Rizzuto et al., 1998).
This later domain, though highly conserved and strongly immuno-
genic, appears to be poorly exposed and rarely a target for antibody-
mediated neutralization (Decker et al., 2005). Our identiﬁcation of a
neutralization cluster-associated amino acid signature on the rim of
this region suggests that it participates to some extent in the
neutralizing activity of HIV-1-positive plasma samples.
Additional signatures of interest in gp120 involved PNLG at
positions 295, 392 and 448. All three PNLG have been shown to
participate in the carbohydrate-speciﬁc epitope that is recognized by
the broadly neutralizing mAb, 2G12 (Sanders et al., 2002; Scanlan et
al., 2002). Because these PNLG were absent on the more neutraliza-
tion-sensitive viruses, it is doubful that 2G12-like antibodies were
responsible for the neutralization cluster-associated signatures.
Consistent with this notion, a loss of PNLG at position 295 is strongly
associated with broad resistance to 2G12 in subtype C viruses (Binley
et al., 2004; Bures et al., 2002; Gray et al., 2006; Li et al., 2006b). It
seemsmore likely that these three PNLG play a central role in masking
neutralizing epitopes recognized by HIV-1-positive plasma samples.
Fourteen neutralization cluster-associated amino acid signatures
occurred in the ectodomain and CT of gp41, suggesting a dual role for
this glycoprotein in shaping the neutralization phenotype of the virus.
One role would be for epitopes in the gp41 ectodomain to serve
directly as targets for neutralizing antibodies. The CT, being internal
and presumably inaccessible to antibodies, would play a different role,
perhaps by regulating Env incorporation during virus assembly
(Berlioz-Torrent et al., 1999; Byland et al., 2007; Freed and Martin,
1996; Murakami and Freed, 2000; Yu et al., 1993; Yuste et al., 2004)
and by mediating allosteric changes that affect epitopes in gp120 and
the gp41 ectodomain (Edwards et al., 2002; Gray et al., 2008; Kalia et
al., 2005; Vzorov et al., 2005). Among the ﬁve signatures in the gp41
ectodomain, one occurred at position 667within theMPER that is part
of the epitope for broadly neutralizing mAb 2F5 (Zwick et al., 2005).
Notably, no signatures occurred in the epitope for the broadly
neutralizing MPER-speciﬁc mAb, 4E10. Antibodies with 2F5- and
4E10-like speciﬁcity are extremely rare in HIV-1-positive serum
samples (Gray et al., 2007; Yuste et al., 2006); however, other
MPER-speciﬁc antibodies might be present that could potentially
neutralize (Gray et al., 2007, 2008). The location of four additional
signatures outside the MPER suggests that other regions of the gp41
ectodomain are important for antibody-mediated virus neutralization.
An additional role for the gp41 CT is suggested by multiple signatures
that occurred in and around regions that have been implicated in
modulating neutralization by anti-gp41 and anti-gp120 Abs (Edwards
et al., 2002; Gray et al., 2008; Kalia et al., 2005; Vzorov et al., 2005).
Two additional signatures (positions 750 and 803) occurred in regions
that have been shown to regulate Env incorporation (Blot et al., 2003;
Bültmann et al., 2001; Lopez-Vergès et al., 2006). A recent study found
that increased Env spike density on SIV can be associated with
decreased neutralization-sensitivity (Yuste et al., 2005).This study began out of interest to gain information on the genetic
and neutralization properties of functional molecular clones of newly
transmitted HIV-1 variants from India. Because of the large multi-
subtype panel of viruses characterized, the study evolved to examine
complex patterns of plasma neutralizing activity as they relate to Env
sequence variation. The two goals are inter-related in so much as the
results help to explain how a monophyletic lineage of Indian Envs can
exhibit extensive antigenic diversity. Thus, relatively small genetic
changes that alter the number of N-linked glycans on gp120, modify
the size of gp120 and its variable loops, and that introduce amino acid
substitutions at one or more key positions in gp120 and gp41, all
appear to shape the general neutralization phenotype of the virus. We
caution that these results are preliminary and need to be conﬁrmed
with much larger and diverse sets of HIV-1-positive serologic
reagents. Moreover, detailed molecular studies are needed to validate
the neutralization cluster-associated amino acid signatures identiﬁed
in this study. Caveats worth mentioning are that most of the Env
clones used here, including the 10 Indian Envs, were derived by bulk
PCR ampliﬁcation of PBMCDNA, and theywere selected on the basis of
high infectivity in TZM-bl cells. A recent report describes a limiting
dilution method for single genome PCR ampliﬁcation (SGA) from
plasma virion RNA that avoids potential artifacts caused by Taq-
induced nucleotide substitutions and template switching (Salazar-
Gonzalez et al., 2008). It is uncertain to what extent, if any, these
potential artifacts might have impacted our results. It also remains to
be seen whether our results are biased for clones that exhibit high
infectivity in TZM-bl cells. These uncertainties may become apparent
as similar studies are conducted with multiple SGA-derived Env
clones. At the very least, the Indian Env clones described here should
be useful as an initial panel of Env-pseudotyped viruses for
standardized assessments of vaccine-elicited neutralizing Ab
responses in India. They will also be useful for detailed investigations
of epitope diversity and Env structure in a monophyletic lineage of
HIV-1 variants that appear to be drivingmuch of the epidemic in India.
It will be of particular interest to see how the neutralization properties
of these Envs from Pune compare to Envs from other regions in India,
as well as to Indian Envs that are more recent in the epidemic.
Materials and methods
Viral isolates
Viruses were isolated from 10 anti-retroviral (ARV)-naïve, HIV-1
infected subjects (00836, 16845, 16936, 25711, 25925, 0013095,
001428, 16055, 26191, 25710) who were identiﬁed in a prospective
cohort of patients attending sexually transmitted diseases (STD)
clinics in Pune (Maharashtra), India and the surrounding area
(Mehendale et al., 2002). All infections were acquired through
heterosexual contact. In this cohort, consenting HIV-1 seronegative
patients were screened for HIV antibodies at three month intervals
(Recombigen HIV-1/HIV-2, Cambridge Biotech, Galway, Ireland and
Genetic Systems, Genelabs Diagnostics, Singapore). Those who tested
negative for HIV antibody but positive for HIV-1 p24 antigen (Coulter
HIV-1 p24 assay, Coulter Corporation, USA) were recruited for study.
Blood samples were collected in EDTA tubes (Becton Dickinson,
Singapore) soon after conﬁrmation of p24 antigenemia and enroll-
ment into the study.
Peripheral blood mononuclear cells (PBMC) were separated from
the whole blood by using Ficoll-Hypaque (Sigma, USA) and stored in
liquid nitrogen. Plasma was collected and stored at −70 °C. Viruses
were isolated by using a PBMC co-cultivation method (Kulkarni et al.,
1999) with PBMC from the ﬁrst sample collected after conﬁrmation of
p24 antigen status. HIV-1 RNA was quantiﬁed in stored plasma
samples by reverse transcriptase polymerase chain reaction (RT-PCR)
using Amplicor HIV-1 Monitor test (version 1.5 Roche Molecular
Systems, Branchburg, NJ, USA). Viruses were identiﬁed as HIV-1
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assay (HMA) as described earlier (Gadkari et al., 1998) and reagents
provided by NIH AIDS Research and Reference Reagent Program.
Absolute CD4 cell counts were estimated on freshly collected blood
samples by using two-color ﬂow cytometry (FACSort, Becton Dick-
inson, San Jose, CA, USA).
Other viruses
A functional gp160 clone for the R5 subtype B virus SF162.LS
(Cheng-Mayer et al., 1997; Stamatatos et al., 1998) was obtained from
Leonidas Stamatatos. T-cell line-adapted HIV-1MN (Gallo et al., 1984)
was obtained from Robert Gallo and was propagated in H9 cells as
described (Monteﬁori et al., 1988). Molecularly cloned gp160 genes
representing standard panels of HIV-1 reference strains for subtype B
(6535.3, QH0692.42, SC422661.8, PVO.4, TRO.11, AC10.0.29,
RHPA4259.7, THRO4156.18, REJO4541.67, TRJO4551.58, WITO4160.33,
CAAN5342.A2) and subtype C (Du123.6, Du151.2, Du156.12, Du172.17,
Du422.1, ZM197M.PB7, ZM214M.PL15, ZM215F.PB8, ZM233M.PB6,
ZM249M.PL1, ZM53M.PB12, ZM55F.PB28a, ZM106F.PB9, ZM109F.PB4,
ZM135M.PL10a, CAP45.2.00.G3, CAP210.2.00.E8, CAP244.2.00.D3)
were described previously (Li et al., 2005, 2006b). The Kenyan subtype
A Env clones Q23.17, Q842.d12, Q168.a2, Q416.e2, Q769.d22 and Q259.
d2.17 (Blish et al., 2007) were obtained from Julie Overbaugh. These
subtype B, C and A Envs are all from newly transmitted, sexually
acquired infections. Env clones T257-31, T33-7, 263-8, T250-4, T251-
18, T278-50, T255-34, T266-27, T253-11, T280-5, 271-11, 211-9, 235-
47, 242-14, 269-12 and 252-7 are CRF02_AG from Cameroon; clone
928-28 is CRF02_AG from Cote d'Ivoire. All Env-pseudotyped viruses
were prepared by co-transfection with an env-defective backbone
plasmid (pSG3Δenv) in 293T cells as described (Li et al., 2005). Most of
these Env clones are available from the NIH AIDS Research and
Reference Reagent Program (ARRRP).
Plasma samples, soluble CD4 (sCD4), and monoclonal antibodies (mAbs)
Plasma samples (numbered 50276 through 75330) were obtained
from 18 ARV-naïve, chronically HIV-1-infected individuals enrolled in
HPTN 034; blood was collected from these individuals during routine
visits to clinics at the National AIDS Research Institute, Pune, India
during 2005 and 2006. Plasma samples from ARV-naive, chronically
HIV-1-infected blood donors were obtained from the South African
National Blood Services in Johannesburg, South Africa, as contributed
to this study by Lynn Morris. A larger set of these latter blood bank
plasma samples was tested for neutralization activity against three
subtype C Env-pseudotyped viruses (Du151.2, Du156.12, and
Du172.17) and those with greatest neutralizing activity (BB8, BB12,
BB28, BB55, BB70, and BB106) were selected for characterization here.
Plasma pools for subtypes B, C, and D were described previously (Li et
al., 2005). Each plasma pool was comprised of plasma from 6–10
subjects who had pure subtype infections as veriﬁed by full HIV-1
genome sequencing of DNA from cryopreserved PBMC. A normal
plasma pool was prepared from leukopaks from 4 HIV-1-negative
subjects (BRT Laboratories, Inc., Baltimore, MD). All plasma samples
were heat inactivated at 56 °C for 1 h prior to assay. Informed consent
was obtained from study participants as approved by local institu-
tional review boards and biosafety committees. Blood bank samples
were obtained from anonymous donors.
Recombinant sCD4 comprising the full-length extracellular
domain of human CD4 and produced in Chinese hamster ovary cells
was obtained from Progenics Pharmaceuticals, Inc. (Tarrytown, NY).
Human anti-gp120 mA b IgG1b12 was kindly provided by Dennis
Burton (The Scripps Research Institute, La Jolla, CA). The human anti-
gp120 carbohydrate-speciﬁc mAb 2G12, and the human anti-gp41 mA
bs 2F5 and 4E10, were purchased from PolyMun Scientiﬁc (Vienna,
Austria). TriMab (used as a positive control) is a mixture of threemAbs(IgG1b12, 2G12, and 2F5) and was prepared as a 1 mg/ml stock
solution containing 333 μg of each mAb/ml in phosphate-buffered
saline, pH 7.4 (Li et al., 2005).
Cells
TZM-bl cells (also called JC53-BL)were obtained from the ARRRP as
contributed by John Kappes and Xiaoyun Wu. This is a genetically
engineered HeLa cell clone that expresses CD4, CXCR4, and CCR5 and
contains Tat-responsive reporter genes for ﬁreﬂy luciferase and
Escherichia coli β-galactosidase under regulatory control of an HIV-1
long terminal repeat (Platt et al., 1998; Wei et al., 2002). 293T/17 cells
were obtained from the American Type Culture Collection (Catalog no.
11268). Both cell lines were maintained in Dulbecco's modiﬁed Eagle's
medium (Gibco BRL Life Technologies) containing 10% heat-inacti-
vated fetal bovine serum (HyClone) and 50 μg gentamicin/ml in
vented T-75 culture ﬂasks (Corning-Costar). Cultures were incubated
at 37 °C in a humidiﬁed 5% CO2-95% air environment. Cell monolayers
were split 1:10 at conﬂuence by treatment with 0.25% trypsin, 1 mM
EDTA (Invitrogen).
Ampliﬁcation and cloning of env/rev DNA cassettes
Complete env–rev cassettes were cloned from the DNA of cultured
PBMC infected with each of the 10 Indian primary HIV-1 isolates
described above. Brieﬂy, fresh phytohemagglutinin-stimulated PBMC
from healthy HIV-1-negative donors were inoculated with primary
isolates that had been derived by PBMC co-culture. Infected PBMC
were used as a source of DNA for PCR ampliﬁcation and cloning of
env–rev cassettes as described (Li et al., 2005). PCR products were
inserted directly into pcDNA 3.1D/V5-His-TOPO (Invitrogen Corp.,
Carlsbad, CA). Plasmid minipreps from multiple colonies of trans-
formed JM109 cells were screened by restriction enzyme digestion for
full-length inserts. Clones with inserts in the correct orientation were
screened by co-transfection with an env-deﬁcient HIV-1 (pSG3Δenv)
backbone in 293T cells to produce Env-pseudotyped viruses. Infec-
tious Env-pseudotyped viruses were identiﬁed in a luciferase (Luc)
reporter gene assay in TZM-bl cells as described (Li et al., 2005). Env
clones conferring highest infectivity were selected for further
characterization.
DNA sequence and phylogenetic analysis
Sequence analysis was performed by cycle sequencing and BigDye
terminator chemistry with automated DNA Sequencer (Applied
Biosystems, Inc; Models 3100 and 3730) as recommended by the
manufacturer. Individual sequence fragments for each env clone were
assembled and edited using the Sequencher program 4.2 (Gene Codes
Corp., Ann Arbor, MI). Nucleotide and deduced Env amino acid
sequences were initially aligned using CLUSTALW (Higgins and Sharp,
1989; Thompson et al., 1994) and manually adjusted for an optimal
alignment using MASE (Faulkner and Jurka, 1988). A maximum
likelihood tree was created assuming that the nucleotide sites evolve
independently according to the General Reversible Model, with site
rate variation estimated using maximum likelihood (Korber et al.,
2000). The nine parameters of the model, as well as the rate at each
site, were estimated using likelihood analysis. The reliability of
branching orders was assessed by bootstrap analysis. Complete
sequences of the gp160 genes are available from GenBank and the
Los Alamos HIV Sequence Database (refer to Table 1 for accession
numbers).
Pseudovirus preparation, titration and analysis of coreceptor usage
Env-pseudotyped viruses were prepared, titrated and analyzed for
coreceptor usage as described (Li et al., 2005). Brieﬂy, exponentially
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plasmid and an env-deﬁcient HIV-1 backbone vector (pSG3ΔEnv).
Pseudovirus-containing culture supernatants were harvested 2 days
after transfection, ﬁltered (0.45 μm pore size) and stored at −80 °C in
1 ml aliquots. The 50% tissue culture infectious dose (TCID50) was
determined in TZM-bl cells. Coreceptor usagewas determined in TZM-
bl cells by measuring reductions in infectivity in the presence of the
CXCR4 and CCR5 antagonists AMD 3100 and TAK-779, respectively.
Neutralization assay
Neutralizing Abs were measured as a function of reductions in
luciferase reporter gene expression after a single round of infection in
TZM-bl cells as described (Li et al., 2005; Monteﬁori, 2004). This assay
is a modiﬁed version of the assay as described previously (Wei et al.,
2002, 2003). Brieﬂy, 200 TCID50 of pseudovirus was incubated with
serial 3-fold dilutions of serum sample in triplicate in a total volume of
150 μl for 1 h at 37 °C in 96-well ﬂat-bottom culture plates. Freshly
trypsinized cells (10,000 cells in 100 μl of growth medium containing
75 μg/ml DEAE dextran) were added to each well. One set of control
wells received cells + pseudovirus (virus control) and another set
received cells only (background control). After 48 h incubation, 100 μl
of cells was transferred to 96-well black solid plates (Costar) for
measurements of luminescence using the Britelite Luminescence
Reporter Gene Assay System (PerkinElmer Life Sciences). The 50%
inhibitory dose (ID50) was deﬁned as either the serum dilution or
sample concentration (in the case of sCD4 and mAbs) that caused a
50% reduction in RLU compared to virus control wells after subtraction
of background RLU. Assay stocks of Env-pseudotyped viruses were
prepared by transfection in 293Tcells andwere titrated in TZM-bl cells
as described (Li et al., 2005; Monteﬁori, 2004).
Two-dimensional hierarchical clustering analyses
Neutralization data were clustered as described (Binley et al.,
2004), using the hierarchical clustering function (hclust) and display
function (Heatmap) of the R statistical computing environment
(www.r-project.org). The “hclust”, which employs an agglomerative
clustering algorithm to cluster both the rows and columns of tabular
data separately, was applied to tabular neutralization data containing
log (IC50) values. Algorithm speciﬁcations of Euclidean distance and
“complete” method of agglomeration were used. After individually
clustering the rows (pseudoviruses) and the columns (plasmas), the
function “Heatmap” then simultaneously displayed the separate
pseudovirus and plasma clusterings in one graphic called a Heatmap.
Bootstrap values of cluster stability were obtained via the “pvclust”
package.
Correlating genetic mutation to neutralization phenotype
Phylogenetically corrected associations of genetic mutation and
neutralization phenotype clusters were obtained using the techniques
developed by Bhattacharya et al. (2007) and applied in the context of
associating genetic mutations with HLA.
Structural mapping of signature positions
The core structure of gp120 corresponding to the X-ray structure of
CD4-bound YU2 gp120 (Kwong et al., 2000) was used for mapping
cluster associated mutations. Variable loops V1V2 and V3 were
modeled for clarity as described previously (Blay et al., 2006).
Modeling calculations were performed using a modiﬁed version of
AMBER (Pearlman et al., 1995). Signature positions were mapped onto
this structure based on the alignmentof sequences. Three-dimensional
images were generated using VMD (Humphrey et al., 1996). The
positional numbering refers to HXB2.Statistical analyses
The neutralizing potencies of HIV-1-positive plasma samples
against different sets of Env-pseudotyped viruses were compared by
using two-tailed Mann Whitney tests with a 95% conﬁdence interval
(GraphPad Prism software, San Diego, CA). For the comparison of
neutralization titers, valuesb20 (lowest sample dilution tested) were
assigned a value of 10. Differences were considered signiﬁcant if p
wasb0.05. Other statistical analyses that were used are described in
the text.
Nucleotide sequence accession numbers
GenBank accession numbers for the Indian HIV-1 gp160 sequences
in this study are EF117265.1 – EF117274.1.
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